Synthetic Cannabinoids Based on Indole, Indazole, Benzimidazole and Carbazole Scafolds

Total Page:16

File Type:pdf, Size:1020Kb

Synthetic Cannabinoids Based on Indole, Indazole, Benzimidazole and Carbazole Scafolds Forensic Toxicology (2018) 36:385–403 https://doi.org/10.1007/s11419-018-0415-z ORIGINAL ARTICLE Pharmacological evaluation of new constituents of “Spice”: synthetic cannabinoids based on indole, indazole, benzimidazole and carbazole scafolds Clara T. Schoeder1,3 · Cornelius Hess2 · Burkhard Madea2 · Jens Meiler4 · Christa E. Müller1,3 Received: 16 March 2018 / Accepted: 5 April 2018 / Published online: 26 April 2018 © The Author(s) 2018 Abstract Purpose In the present study we characterized a series of synthetic cannabinoids containing various heterocyclic scafolds that had been identifed as constituents of “Spice”, a preparation sold on the illicit drug market. All compounds were further investigated as potential ligands of the orphan receptors GPR18 and GPR55 that interact with some cannabinoids. Methods The compounds were studied in radioligand binding assays to determine their afnity for human cannabinoid ­CB1 and ­CB2 receptors expressed in CHO cells, and in cAMP accumulation assays to study their functionality. Results Structure-activity relationships were analyzed. The most potent ­CB1 receptor agonist of the present series MDMB- FUBINACA (12) (Ki = 98.5 pM) was docked into the human CB­ 1 receptor structure, and a plausible binding mode was identifed showing high similarity with that of the co-crystallized THC derivatives. MDMB-CHMCZCA (41) displayed a unique profle acting as a full agonist at the ­CB1 receptor subtype, but blocking the ­CB2 receptor completely. Only a few weakly potent antagonists of GPR18 and GPR55 were identifed, and thus all compounds showed high CB receptor selectiv- ity, mostly interacting with both subtypes, ­CB1 and ­CB2. Conclusions These results will be useful to assess the compounds’ toxicological risks and to guide legislation. Further stud- ies on 41 are warranted. Keywords Pharmacological evaluation of new synthetic cannabinoids · Afnities for ­CB1 and ­CB2 receptors · β-Arrestin assay at GPR18 and GPR55 · cAMP accumulation assay · Benzimidazole and carbazole · Structure-activity relationships Introduction A challenging issue for forensic toxicologists and law mak- Electronic supplementary material The online version of this ers is how to efectively respond to the constantly changing article (https​://doi.org/10.1007/s1141​9-018-0415-z) contains new psychoactive substances on the illicit drug market [1]. supplementary material, which is available to authorized users. Among these, synthetic cannabinoids feature prominently [2, 3]. Between 2008, when so-called “Spice” products [4] * Christa E. Müller christa.mueller@uni‑bonn.de containing synthetic cannabinoids began to appear on the drug market, and 2016, 169 new synthetic cannabinoids 1 PharmaCenter Bonn, Pharmaceutical Institute, were confscated and identifed [2]. Most of them were dis- Pharmaceutical Chemistry I, University of Bonn, An der covered as powders, often in bulk amounts, while others Immenburg 4, 53121 Bonn, Germany 2 were found in preparations of plant materials, e.g., minced Institute of Forensic Medicine, Forensic Toxicology, herbs, onto which solutions of the cannabinoids had been University Hospital of Bonn, Stiftsplatz 12, 53111 Bonn, Germany sprayed [5]. These substances have been shown to bind to and in many cases activate cannabinoid (CB) receptors. 3 Research Training Group 1873, University of Bonn, 53127 Bonn, Germany CB receptors are divided into two subtypes, ­CB1 and ­CB2, which belong to the large family of rhodopsin-like class A 4 Departments of Chemistry and Pharmacology, Vanderbilt University, Stevenson Center, Station B 351822, Nashville, G protein-coupled receptors (GPCRs) [6]. Both CB receptor TN 37235, USA subtypes are coupled to G­ i proteins including a reduction in Vol.:(0123456789)1 3 386 Forensic Toxicology (2018) 36:385–403 intracellular cAMP levels. The main psychoactive efects restricted. Newly discovered SARs of synthetic cannabinoids of cannabinoids are mediated by the CB 1 receptor, which is will, therefore, provide a basis for future amendments. How- predominantly expressed in the central nervous system [7], ever, in many cases, only limited information is available while CB2 receptor expression in the brain is restricted to regarding the activity of new substances. Both the afnity microglial cells [8, 9]. CB2 receptors are highly expressed in of a drug for its receptor and its ability to produce an ago- the immune system, for example in tonsils and spleen [10, nistic response are important features, and these should be 11]. Activation of the CB2 receptor is considered as a new determined according to a compound’s chemical structure. therapeutic option for the treatment of infammatory diseases For important classes of synthetic cannabinoids, at least four and pain [12, 13]. structural components, which have frstly been described by The plant-derived partial CB1 and CB2 receptor agonist Hufman et al. and were later refned by the European Moni- Δ9-tetrahydrocannabinol (Δ9-THC, 1, Fig. 1) is used in toring Centre for Drugs and Drug Addiction (EMCDDA), therapy to target muscle spasms, nausea and cachexia [14]. are of importance (see Fig. 2 [3]): (1) a heterocyclic core The synthetic compound CP55,940 (2, Fig. 1) represents a consisting of indole or indazole with diferent substitutions; potent full agonist at both receptor subtypes. A CB1 receptor (2) a linker, e.g., an ester, amide or ketone; (3) a bulky lipo- antagonist, rimonabant, had been approved for the treatment philic residue (R1), e.g., a heterocyclic or aryl substituent, of obesity but was later withdrawn from the market due to but in newer synthetic cannabinoids a lipophilic amino acid side efects resulting in depression and an increased suicide can also be found; and (4) a residue (R 2) which is a hydro- rate [15]. phobic “side chain” attached to the nitrogen atom of the The prevalence for the use of illegal psychoactive sub- indole or the indazole ring system [21, 22]. The compound stances in Europe by 15–16 year-old teenagers was estimated JWH-018 (3, see Fig. 1), a potent CB1 and CB2 receptor in 2015 to be about 4% [5]. Synthetic CB1 receptor agonists agonist, displays the basic features of this compound class are abused as an alternative to natural marijuana due to their and was one of the frst synthetic cannabinoids identifed in psychoactive and analgesic efects. For synthetic cannabi- herbal blends for abuse [23, 24]. The common features of noids more and more severe side efects and intoxications known synthetic cannabinoids are depicted in Fig. 2. are reported; they are predominantly neurologic symptoms, In a previous study [25], we had determined the phar- but acute organ toxicity has also been observed [16]. In the macological properties of 48 synthetic cannabinoids USA, the principle of enumeration is used to restrict newly collected by the Institute of Forensic Medicine of the discovered synthetic cannabinoids, and every single syn- University of Bonn. In the present study, we investi- thetic cannabinoid has to be individually listed by name in gated the affinities and functional properties of a new the US List of Schedule I drugs [17]. In Germany new syn- series of 42 synthetic cannabinoids, 16 of which have thetic cannabinoids are legally controlled since November not been reported as cannabinoid receptor ligands before. 2016 when the “Neue-Psychoaktive-Stofe-Gesetz” (NpSG, The investigated set of compounds comprises four dif- New Psychoactive Substances Act) was adopted in [18]. ferent core structures. The first three groups (A, B, C, Similar regulations exist in Austria and Switzerland [19, see Table 1) represent differently substituted indoles and 20]. All corresponding compounds, the chemical structures indazoles, which are structurally derived from the syn- of which are represented by a general formula in the statute thetic cannabinoids previously introduced by Huffman with known structure-activity relationships (SARs), were et al. and are widely distributed in illicitly sold "Spice" OH O CH3 OH OH H N H H3C CH3 O CH3 H3C H3C CH3 OH CH3 1 ∆9-THC 2 CP55,940 3 JWH-018 CB : K = 0.5 - 5.0 nM CB : K = 9 nM CB1: Ki = 5.05 - 80.3 nM [12] 1 i [12] 1 i [22] CB : K = 0.69 - 2.8 nM CB : K = 2.9 nM CB2: Ki = 3.13 - 75.3 nM [12] 2 i [12] 2 i [22] Fig. 1 Standard cannabinoid CB1/CB2 receptor agonists [12, 22] 1 3 Forensic Toxicology (2018) 36:385–403 387 Fig. 2 Common structural fea- tures of synthetic cannabinoids. The fgure was adopted from the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) [3] and modifed products. In the current study we investigated compounds Radioligand binding assays with L-valinamide (AB)/L-tert-leucinamide (ADB or MAB), methyl-3,3-dimethylbutanoate (MDMB), methyl- Radioligand binding assays were performed as described 3-methylbutanoate (MMB), and 2-methyl-2-phenylpropyl previously [25]. Membrane preparations of Chinese hamster (cumyl) moieties as substituents in the R 1 position. Fur- ovary (CHO) cells overexpressing the human CB receptor ther classes of compounds consist of carbazoles (E), sub- subtype CB1 or CB 2 were incubated in the presence of the stituted in position 3, and benzimidazole derivatives (F). test compound and the radioligand [3H]CP55,940 (0.1 nM, Radioligand binding and cAMP functional studies on see Fig. 1) (Perkin-Elmer Life Sciences, Rodgau-Jügesheim, CB1 and CB2 receptors were complemented by CB1 recep- Germany), for 2 h. Bound and unbound radioligand were tor modeling and docking of the most potent CB 1 receptor separated by rapid fltration through glass fber GF/C-flters agonist of the present series to predict its interactions. We (Perkin-Elmer, Boston, MA, USA), using a Brandel 96-well further tested all compounds for their ability to activate or Harvester (Brandel, Gaithersburg, MD, USA). Radioactivity block the two orphan GPCRs GPR18 and GPR55, both of on the flters was determined by liquid scintillation count- which are known to interact with cannabinoids [26–29]. ing. Three separate experiments were performed, each in We discuss SARs of the newly investigated compounds, duplicates.
Recommended publications
  • Swedish Code of Statutes
    1. ------IND- 2018 0506 S-- EN- ------ 20190508 --- --- FINAL Swedish Code of Statutes Ordinance amending the Ordinance (1999:58) banning certain products SFS 2018:1587 that are harmful to health Published Issued on 4 October 2018 on 9 October 2018 The Government hereby lays down1 that the annex to the Ordinance (1999:58) prohibiting certain products that are harmful to health shall read as set out below. ___________ This ordinance shall enter into force on 12 November 2018. On behalf of the government ANNIKA STRANDHÄLL Kjell Rempler (Ministry of Health and Social Affairs) 1 See Directive (EU) 2015/1535 of the European Parliament and of the Council of 9 September 2015 laying down a procedure for the provision of information in the field of technical regulations and of rules on Information Society services. 2 Annex SFS 2018:1587 List of products to be regarded as products that are harmful to health in accordance with the Ordinance prohibiting certain products that are harmful to health N-methyl-1-(3,4-methylenedioxyphenyl)-2-butylamine (MBDB) 1-(3,4-methylenedioxyphenyl)-2-butylamine (BDB) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT) 5-methoxy-alphamethyltryptamine (5-MeO-AMT) 2,5-dimethoxy-4-ethylphenethylamine (2C-E) alpha-methyltryptamine (AMT) 2,5-dimethoxy-4-chlorophenethylamine (2C-C) 2,5-dimethoxy-4-methylphenethylamine (2C-D) 4-acetoxy-N,N-diisopropyltryptamine (4-AcO-DiPT) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT) gamma-butyrolactone (GBL) 1,4-butanediol (1,4-BD) 4-acetoxy-N,N-methylisopropyltryptamine
    [Show full text]
  • Recommended Methods for the Identification and Analysis of Synthetic Cannabinoid Receptor Agonists in Seized Materials (Revised and Updated)
    Recommended methods for the Identification and Analysis of Synthetic Cannabinoid Receptor Agonists in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Photo credits: UNODC Photo Library; UNODC/Ioulia Kondratovitch; Alessandro Scotti. Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Synthetic Cannabinoid Receptor Agonists in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2020 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases, but any modification has to be validated before it is integrated into laboratory routines. Mention of names of firms and commercial products does not imply theendorsement of the United Nations. ST/NAR/48/REV.1 © United Nations, July 2020. All rights reserved, worldwide The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Services of the United Nations Office on Drugs and Crime (UNODC) (LSS, headed by Dr.
    [Show full text]
  • Synthetic Cannabinoids Synthetic Cannabinoids-1
    Synthetic Cannabinoids-1 Synthetic Cannabinoids ™ (HEIA ) For the detection of JWH-018, JWH-073, AM-2201 & their major metabolites Homogeneous Enzyme Immunoassay (HEIA™) K2-3 K2-2 K2-1 Assay Specifications Sensitivity: 100% LC-MS/MS Confirmation Specificity: 87.5% Methodology: Homogeneous Enzyme Immunoassay Accuracy: 96.9% Positive Negative Cutoff: 10 ng/mL HEIA Positive 48 2* Calibrator: JWH-018 N-pentanoic acid (10 ng/mL) Negative 0 14 *2 discrepant specimens that screened negative were borderline negative at 10 ng/mL cutoff. AB-PINACA ADB-PINACA UR-144 XLR11 JWH-018 JWH-073 AM-2201 Immunalysis now offers three distinct Synthetic Cannabinoid Homogeneous Enzyme Immunoassays (HEIA™) Cross-Reactivity N/D = Cross-Reactivity < 0.05% for the detection of Synthetic Cannabinoids in urine. Our assays, geared towards the detection of JWH-018, JWH-073, AM-2201, UR-144, XLR11 and their metabolites, are now complemented by a NEW assay targeted Analyte Analyte Concentration JWH-018 N-pentanoic acid Cross-Reactivity at the next generation, AB-PINACA and ADB-PINACA compounds found in the current Spice or K2 products. (ng/mL) Equivalent (ng/mL) (%) Together, these assays detect Schedule I controlled substances and provide the most comprehensive screening JWH-018 N-pentanoic acid 10 10 100 tool for your automated chemistry analyzer. JWH-018 N-(5-hydroxypentyl) 15 10 67 JWH-018 4-hydroxyindole 135 10 7.4 JWH-018 5-hydroxyindole 40 10 25 AM-2201 N-(4-hydroxypentyl) 12 10 83 Liquid Stable, Ready to Use AM-2201 6-hydroxyindole 20 10 50 JWH-073 N-(4-hydroxybutyl)
    [Show full text]
  • Retrospective Identification of Synthetic Cannabinoids in Forensic Toxicology Casework Using Archived High Resolution Mass Spectrometry Data Author(S): Alex J
    The author(s) shown below used Federal funding provided by the U.S. Department of Justice to prepare the following resource: Document Title: Retrospective Identification of Synthetic Cannabinoids in Forensic Toxicology Casework using Archived High Resolution Mass Spectrometry Data Author(s): Alex J. Krotulski, Ph.D., Amanda L.A. Mohr, MSFS, D-ABFT-FT, Barry K. Logan, Ph.D., F-ABFT Document Number: 255668 Date Received: November 2020 Award Number: 2017-R2-CX-0021 This resource has not been published by the U.S. Department of Justice. This resource is being made publically available through the Office of Justice Programs’ National Criminal Justice Reference Service. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. Title: Retrospective Identification of Synthetic Cannabinoids in Forensic Toxicology Casework using Archived High Resolution Mass Spectrometry Data Authors: Alex J Krotulski, PhD, Amanda LA Mohr, MSFS, D-ABFT-FT, and Barry K Logan, PhD, F-ABFT Organization: Center for Forensic Science Research and Education at the Fredric Rieders Family Foundation, Willow Grove, PA, USA Award Number: 2017-R2-CX-0021 This resource was prepared by the author(s) using Federal funds provided by the U.S. Department of Justice. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. Abstract Since 2008, synthetic cannabinoids have continued to proliferate and challenge the forensic science community due to rapid appearance and diverse chemistry.
    [Show full text]
  • How Present Synthetic Cannabinoids Can Help Predict Symptoms in the Future
    MOJ Toxicology Mini Review Open Access How present synthetic cannabinoids can help predict symptoms in the future Abstract Volume 2 Issue 1 - 2016 New synthetic cannabinoids appear regularly in the illicit drug market, often in response to Melinda Wilson-Hohler,1 Wael M Fathy,2 legal restrictions. These compounds are characterized by increasing binding affinities (Ki) 3 to CB1 and CB2 receptors. Increasing affinity to CB receptors can occur by substitution of a Ashraf Mozayani 1Consultant, The Forensic Sciences, USA halogen on the terminal position of the pentyl chain of the classical synthetic cannabinoids. 2Post-Doctoral Fellowship, Texas Southern University, USA & Fluorination of the aliphatic side chain of established cannabinoid agonists is a popular Toxicologist, Ministry of Justice, Egypt pathway of modifying existing active drugs and synthesizing novel drugs to increase 3Professor, Barbara Jordan-Mickey Leland School of Public potency. Biological impacts of these compounds that have been reported include seizures, Affairs, Texas Southern University, USA body temperature losses that may lead to cardiac distress, as well as cases reporting delirium and severe neural incapacities. These symptoms have been reported in case Correspondence: Ashraf Mozayani, Executive Director of reports with evidence that like their cannabinoid counterparts, these compounds distribute Forensic Science and Professor, Barbara Jordan-Mickey Leland post-mortem into a variety of tissues, especially adipose tissue. Researchers have detected School of Public Affairs, Texas Southern University, USA, and identified certain synthetic cannabinoid compounds on botanicals using a variety of Tel17132526556, Email [email protected] separation and detection systems such as GC-FID and GC-MS, as well as LC-MS/MS and NMR.
    [Show full text]
  • Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)
    Model Scheduling New/Novel Psychoactive Substances Act (Third Edition) July 1, 2019. This project was supported by Grant No. G1799ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact NAMSDL at [email protected] or (703) 229-4954 with any questions about the Model Language. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: NATIONAL ALLIANCE FOR MODEL STATE DRUG 1 LAWS, 1335 North Front Street, First Floor, Harrisburg, PA, 17102-2629. Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)1 Table of Contents 3 Policy Statement and Background 5 Highlights 6 Section I – Short Title 6 Section II – Purpose 6 Section III – Synthetic Cannabinoids 13 Section IV – Substituted Cathinones 19 Section V – Substituted Phenethylamines 23 Section VI – N-benzyl Phenethylamine Compounds 25 Section VII – Substituted Tryptamines 28 Section VIII – Substituted Phenylcyclohexylamines 30 Section IX – Fentanyl Derivatives 39 Section X – Unclassified NPS 43 Appendix 1 Second edition published in September 2018; first edition published in 2014. Content in red bold first added in third edition. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws.
    [Show full text]
  • Appendix-2Final.Pdf 663.7 KB
    North West ‘Through the Gate Substance Misuse Services’ Drug Testing Project Appendix 2 – Analytical methodologies Overview Urine samples were analysed using three methodologies. The first methodology (General Screen) was designed to cover a wide range of analytes (drugs) and was used for all analytes other than the synthetic cannabinoid receptor agonists (SCRAs). The analyte coverage included a broad range of commonly prescribed drugs including over the counter medications, commonly misused drugs and metabolites of many of the compounds too. This approach provided a very powerful drug screening tool to investigate drug use/misuse before and whilst in prison. The second methodology (SCRA Screen) was specifically designed for SCRAs and targets only those compounds. This was a very sensitive methodology with a method capability of sub 100pg/ml for over 600 SCRAs and their metabolites. Both methodologies utilised full scan high resolution accurate mass LCMS technologies that allowed a non-targeted approach to data acquisition and the ability to retrospectively review data. The non-targeted approach to data acquisition effectively means that the analyte coverage of the data acquisition was unlimited. The only limiting factors were related to the chemical nature of the analyte being looked for. The analyte must extract in the sample preparation process; it must chromatograph and it must ionise under the conditions used by the mass spectrometer interface. The final limiting factor was presence in the data processing database. The subsequent study of negative MDT samples across the North West and London and the South East used a GCMS methodology for anabolic steroids in addition to the General and SCRA screens.
    [Show full text]
  • Cannabinoid-Like Effects of Five Novel Carboxamide Synthetic Cannabinoids T ⁎ Michael B
    Neurotoxicology 70 (2019) 72–79 Contents lists available at ScienceDirect Neurotoxicology journal homepage: www.elsevier.com/locate/neuro Full Length Article Cannabinoid-like effects of five novel carboxamide synthetic cannabinoids T ⁎ Michael B. Gatch , Michael J. Forster Department of Pharmacology and Neuroscience, Center for Neuroscience Discovery, University of North Texas Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX, 76107-2699, USA ARTICLE INFO ABSTRACT Keywords: A new generation of novel cannabinoid compounds have been developed as marijuana substitutes to avoid drug Drug discrimination control laws and cannabinoid blood tests. 5F-MDMB-PINACA (also known as 5F-ADB, 5F-ADB-PINACA), MDMB- Locomotor activity CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA (also known as FUB-AMB, Rat MMB-FUBINACA) were tested for in vivo cannabinoid-like effects to assess their abuse liability. Locomotor Mouse activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose Abuse liability ranges and times of peak effect. Discriminative stimulus effects were tested in rats trained to discriminate Δ9- tetrahydrocannabinol (3 mg/kg, 30-min pretreatment). 5F-MDMB-PINACA (ED50 = 1.1 mg/kg) and MDMB- CHIMICA (ED50 = 0.024 mg/kg) produced short-acting (30 min) depression of locomotor activity. ADB-FUBINACA (ED50 = 0.19 mg/kg), and AMB- FUBINACA (ED50 = 0.19 mg/kg) depressed locomotor activity for 60–90 min; whereas MDMB-FUBINACA (ED50 = 0.04 mg/kg) depressed locomotor activity for 150 min. AMB-FUBINACA produced tremors at the highest dose tested. 5F-MDMB-PINACA (ED50 = 0.07), MDMB- CHIMICA (ED50 = 0.01 mg/kg), MDMB-FUBINACA (ED50 = 0.051 mg/kg), ADB-FUBINACA (ED50 = 0.075 mg/ 9 kg) and AMB-FUBINACA (ED50 = 0.029) fully substituted for the discriminative stimulus effects of Δ -THC following 15-min pretreatment.
    [Show full text]
  • Alcohol and Drug Abuse Subchapter 9
    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four-hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
    [Show full text]
  • JWH-073 Critical Review Report Agenda Item 4.11
    JWH-073 Critical Review Report Agenda item 4.11 Expert Committee on Drug Dependence Thirty-eight Meeting Geneva, 14-18 November 2016 38th ECDD (2016) Agenda item 4.11 JWH-073 Page 2 of 29 38th ECDD (2016) Agenda item 4.11 JWH-073 Contents Acknowledgements ................................................................................................................... 5 Summary ................................................................................................................................... 6 1. Substance identification .................................................................................................... 7 A. International Nonproprietary Name (INN) .................................................................. 7 B. Chemical Abstract Service (CAS) Registry Number .................................................. 7 C. Other Chemical Names ................................................................................................ 7 D. Trade Names ................................................................................................................ 7 E. Street Names ................................................................................................................ 7 F. Physical Appearance .................................................................................................... 7 G. WHO Review History ................................................................................................. 7 2. Chemistry ..........................................................................................................................
    [Show full text]
  • Suspected Synthetic Cannabinoid Receptor Agonist Intoxication: Does
    American Journal of Emergency Medicine 37 (2019) 1846–1849 Contents lists available at ScienceDirect American Journal of Emergency Medicine journal homepage: www.elsevier.com/locate/ajem Original Contribution Suspected synthetic cannabinoid receptor agonist intoxication: Does analysis of samples reflect the presence of suspected agents? ⇑ Collin Tebo a, Maryann Mazer-Amirshahi PharmD, MD, MPH a,b, , Lindsey DeGeorge, MD b, Bradley Gelfand a, Chikarlo Leak, DrPH, MPH c, Samantha Tolliver, PhD c, Diane Sauter, MD, MS a,b a Georgetown University School of Medicine, Washington, DC, United States of America b Department of Emergency Medicine, MedStar Washington Hospital Center, Washington, DC, United States of America c Office of the Chief Medical Examiner, Washington, DC, United States of America article info abstract Article history: Background: There has been a surge in synthetic cannabinoid receptor agonist (SCRA) exposures reported Received 15 November 2018 in recent years. The constituents of SCRA preparations are constantly evolving and rarely confirmed. Received in revised form 20 December 2018 We sought to characterize the constituents of reported SCRA exposures presenting to the emergency Accepted 23 December 2018 department (ED). Methods: Patients who presented to two academic EDs in Washington, DC with reported or suspected SCRA exposure from July 2015–July 2016 were enrolled at the discretion of the treating provider. Keywords: Blood and/or urine samples were obtained as part of routine clinical care and sent to the DC medical Synthetic cannabinoids examiner’s office for identification of known SCRAs with liquid chromatography-mass spectrometry- Synthetic cannabinoid receptor agonists Suspected intoxication mass spectrometry. Standard toxicology screens were additionally performed to determine the presence New psychoactive substances of other drugs of abuse.
    [Show full text]
  • Classes and Structures of Emerging Cannabimimetics and Cathinones
    Classes and Structures of Emerging Cannabimimetics and Cathinones Arthur Berrier Senior Research Chemist Special Testing and Research Laboratory Drug Enforcement Administration Herbal Smoking Blends - SPICE • SPICE and other herbal blends have been sold in head shops and on the Internet since 2006 for their cannabis-like intoxication • The herbal blends sometimes have a fragrance which could include vanilla, potpourri, spice, blueberry, caramel, and strawberry • The plant materials for the different blends have a wide variation in appearance DEA Special Testing and Research Laboratory Emerging Trends Program Herbal Smoking Blends - SPICE • In late 2008, THC Pharma reported the presence of JWH 018, a synthetic cannabimimetic indole in some blends • In early 2009, analogues of CP 47,497 (another synthetic cannabinoid) were also found in some blends by the U. of Freiburg • In early 2009, several European Countries control Herbal Blends/JWH 018/CP 47,497 DEA Special Testing and Research Laboratory Emerging Trends Program Herbal Smoking Blends - SPICE • K2 enters market in April, 2009 • Interest booms in herbal smoking blends in 2009 • Many new products appeared, typically with JWH 018 and JWH 073 • States begin to control the blends/synthetic cannabinoids DEA Special Testing and Research Laboratory Emerging Trends Program Herbal Smoking Blends - SPICE • Products quickly reformulated with new, non- controlled synthetic cannabimimetics • Five of the synthetic cannabimimetics controlled at the Federal level in 2011 • Synthetic Drug Abuse Prevention
    [Show full text]